Spyre Therapeutics Inc. Working Capital to Net Assets Ratio
Spyre Therapeutics Inc. working capital to net assets ratio. Spyre Therapeutics Inc. (SYRE) has a Working Capital to Net Assets ratio of 100.8% as of June 2026. Working capital of $1.11 Billion (current assets of $1.17 Billion minus current liabilities of $63.30 Million) is measured against net assets of $1.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Spyre Therapeutics Inc. (SYRE) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Spyre Therapeutics Inc. (2013–2025)
Working capital to net assets ratio of Spyre Therapeutics Inc. from 2013 to 2025. This chart shows how Spyre Therapeutics Inc.'s Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the ratio stands at 100.8%, reflecting working capital of $1.11 Billion against net assets of $1.10 Billion USD. See Spyre Therapeutics Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Spyre Therapeutics Inc. Working Capital to Net Assets Ratio by Year (2013–2025)
Spyre Therapeutics Inc. working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Spyre Therapeutics Inc. from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see SYRE total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 100.5% | $719.10 Million | $715.24 Million | $777.78 Million | $58.69 Million | ▼ -6.5 pp |
| 2024 | 107.1% | $554.41 Million | $517.80 Million | $608.47 Million | $54.06 Million | ▼ -61.1 pp |
| 2023 | 168.2% | $309.55 Million | $184.02 Million | $341.53 Million | $31.98 Million | ▲ +73.6 pp |
| 2022 | 94.6% | $47.60 Million | $50.30 Million | $62.26 Million | $14.66 Million | ▲ +0.8 pp |
| 2021 | 93.8% | $78.75 Million | $83.94 Million | $98.89 Million | $20.14 Million | ▼ -1.5 pp |
| 2020 | 95.4% | $133.35 Million | $139.83 Million | $149.79 Million | $16.44 Million | ▲ +1.9 pp |
| 2019 | 93.5% | $56.15 Million | $60.08 Million | $74.50 Million | $18.36 Million | ▼ -5.1 pp |
| 2018 | 98.5% | $66.43 Million | $67.43 Million | $76.67 Million | $10.24 Million | ▲ +0.5 pp |
| 2017 | 98.1% | $49.36 Million | $50.34 Million | $54.99 Million | $5.63 Million | ▼ -1.1 pp |
| 2016 | 99.2% | $62.46 Million | $62.97 Million | $66.42 Million | $3.96 Million | ▲ +0.1 pp |
| 2015 | 99.1% | $35.76 Million | $36.10 Million | $38.29 Million | $2.52 Million | ▲ +9.7 pp |
| 2014 | 89.3% | $1.67 Million | $1.87 Million | $2.73 Million | $1.06 Million | ▼ -10.7 pp |
| 2013 | 100.0% | $3.19 Million | $3.19 Million | $4.60 Million | $1.41 Million | — |